CNS Pharmaceuticals (NASDAQ:CNSP) is a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system. The company announced today that its Chief Executive Officer, John Climaco, will present below event at 1:00 p.m. ET on Wednesday, September 28, 2022: Virtual Investor Innovations in Oncology – Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (“GBM”). As part of the virtual event, Climaco will discuss the company’s ongoing potentially pivotal global study evaluating efficacy and safety in the treatment of GBM. Those interested should stop by https://ibn.fm/ktCnW to register for the webinar. A live video webcast of the event will be available on Company websiteand a webcast replay will be available two hours after the live presentation and will be accessible for 90 days.
The full press release can be found at https://ibn.fm/KBYyG
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of drug candidates to treat primary and metastatic cancers of the brain and central nervous system. The Company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline that appears to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious oncological indications affecting the brain and CNS, including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its drug portfolio WP1244, which utilizes anthracycline- and distamycin-based scaffolds for the manufacture of small molecule drugs and is reported to be 500-fold more potent than daunorubicin at inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high brain uptake with antitumor activity. CNS Pharmaceuticals is evaluating the use of…
source_link https://www.digitaljournal.com/pr/cns-pharmaceuticals-nasdaq-cnsp-to-present-at-innovations-in-oncology-event
